Table 3.
Pooled adverse events of endostatin combined with radiotherapy or chemoradiotherapy
| Events | Grade | Incidence, % (95% CI) | ||
|---|---|---|---|---|
| Overall | ECRT group | ERT group | ||
| Radiation pneumonitis | All | 55.9 (31.4–77.9) | 50.7 (20.9–80.0) | 64.1 (27.3–89.4) |
| ≥3 | 10.9 (5.4–20.8) | 11.9 (4.5–27.9) | 9.4 (3.3–24.0) | |
| Radiation esophagitis | All | 77.4 (69.4–83.7) | 89.7 (83.1–93.9) | 55.5 (40.9–69.3) |
| ≥3 | 11.6 (7.6–17.5) | 12.2 (7.6–19.0) | 9.4 (3.3–24.0) | |
| Neutropenia | All | 76.5 (55.6–89.4) | 85.7 (78.5–90.7) | 25.1 (71.6–89.9) |
| ≥3 | 27.8 (14.3–47.0) | 40.1 (30.3–50.8) | 2.1 (0.3–13.7) | |
| Leukopenia | All | 84.5 (49.7–96.8) | 91.8 (78.2–97.2) | 40 |
| ≥3 | 35.5 (18.5–57.7) | 43.4 (27.2–61.2) | 0 | |
| Anemia | All | 54.7 (34.7–73.3) | 70.5 (62.1–77.6) | 28.9 (17.6–43.6) |
| ≥3 | 10.5 (6.2–17.2) | 12.3 (7.6–19.1) | 2.1 (0.3–13.7) | |
| Thrombocytopenia | All | 46.0 (23.2–59.3) | 52.5 (34.2–70.2) | 35.7 (23.1–50.7) |
| ≥3 | 6.9 (2.4–18.3) | 10.1 (3.3–26.7) | 2.1 (0.3–13.7) | |
| Nausea/vomiting | All | 48.2 (32.5–64.2) | 54.1 (38.7–68.7) | 40 |
| ≥3 | 5.8 (2.8–11.6) | 6.3 (3.0–12.9) | 0 | |
| Arrhythmia | All | 25.7 (9.5–52.7) | 37 | 15 |
| ≥3 | 0 | 0 | 0 | |
| Fatigue | All | 58.0 (39.3–74.7) | 67.4 (56.7–76.5) | 40 |
| ≥3 | 2.6 (0.7–8.7) | 2.7 (0.7–1.3) | 0 | |
| Hemorrhage | All | NR | 15.2 (9.0–24.5) | NR |
| ≥3 | NR | 1.8 (0.4–8.3) | NR | |
| Hypertension | All | NR | 2 | NR |
| ≥3 | NR | 0 | NR | |
ERT Endostatin combined with radiotherapy, ECRT Endostatin combined with concurrent chemoradiotherapy, NR Not reported